CYP3A5 and Its Role in Glioblastoma Stemness and Chemoresistance
Author Information
Author(s): Hu Wentao, Cui Xiaoteng, Liu Hongyu, Li Ze, Chen Xu, Wang Qixue, Zhang Guolu, Wen Er, Lan Jinxin, Chen Junyi
Primary Institution: Chinese PLA General Hospital, Nankai University, Beijing, China
Hypothesis
CYP3A5 promotes glioblastoma stemness and chemoresistance through fine-tuning the NAD+/NADH ratio.
Conclusion
CYP3A5 is a promising target for glioblastoma treatment as it enhances tumor stemness and confers resistance to temozolomide.
Supporting Evidence
- CYP3A5 is highly expressed in glioblastoma stem cells and temozolomide-resistant patients.
- Depletion of CYP3A5 impairs self-renewal and temozolomide resistance of glioblastoma stem cells.
- CYP3A5 maintains mitochondrial fitness to promote metabolic adaptation in glioblastoma stem cells.
- CYP3A5 enhances the activity of NAD-dependent enzyme PARP to augment DNA damage repair.
Takeaway
CYP3A5 helps cancer stem cells in the brain survive and resist treatment, making it a potential target for new therapies.
Methodology
The study used machine learning algorithms to construct a glioma stemness-related score (GScore) and performed genetic experiments to assess the impact of CYP3A5 on glioblastoma stem cells.
Participant Demographics
The study included human glioma specimens from patients with high-grade and low-grade gliomas.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website